Bristol widens drug-licensing partnership with Ono

09/21/2011 | Reuters

Bristol-Myers Squibb gained rights to investigational cancer immunotherapy BMS-936558/ONO-4538 in all countries except Taiwan, Japan and South Korea through an expanded agreement with Ono Pharmaceutical. Bristol already had exclusivity in North America. In exchange, Ono gets co-development and -marketing rights in Japan to Orencia, Bristol's rheumatoid arthritis drug.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC